866-997-4948(US-Canada Toll Free)

Acute Promyelocytic Leukemia - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 41 Pages


Global Markets Directs, \'Acute Promyelocytic Leukemia Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acute Promyelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia. Acute Promyelocytic Leukemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Acute Promyelocytic Leukemia.
  • A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acute Promyelocytic Leukemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Acute Promyelocytic Leukemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Acute Promyelocytic Leukemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Acute Promyelocytic Leukemia Overview 6
Therapeutics Development 7
Pipeline Products for Acute Promyelocytic Leukemia - Overview 7
Pipeline Products for Acute Promyelocytic Leukemia - Comparative Analysis 8
Acute Promyelocytic Leukemia - Therapeutics under Development by Companies 9
Acute Promyelocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 10
Acute Promyelocytic Leukemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Acute Promyelocytic Leukemia - Products under Development by Companies 14
Acute Promyelocytic Leukemia - Products under Investigation by Universities/Institutes 15
Acute Promyelocytic Leukemia - Companies Involved in Therapeutics Development 16
Toko Pharmaceutical Industries Co., Ltd. 16
Acute Promyelocytic Leukemia - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Assessment by Therapeutic Class 25
Drug Profiles 27
tamibarotene - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
tamibarotene - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Myc-Max Compounds - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
5-Hydroxy-2, 3-Indole Derivatives - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DR4 Specific Mutant TRAIL Proteins - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Combretastatin Analogues - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Acute Promyelocytic Leukemia - Recent Pipeline Updates 35
Acute Promyelocytic Leukemia - Dormant Projects 36
Acute Promyelocytic Leukemia - Product Development Milestones 37
Featured News & Press Releases 37
Aug 16, 2013: Epizyme Receives Orphan Drug Designation for EPZ-5676 37
Jul 09, 2012: CytRx Receives Notice Of Allowance Of US Patent Application For Tamibarotene Capsule 37
Apr 18, 2011: CytRx Announces Publication Of Peer-Reviewed Case Report Documenting Tamibarotene\'s Successful Elimination Of Recurrent Advanced-Stage Leukemia 38
Dec 07, 2009: CytRx Announces Positive Phase II Results Of Tamibarotene For The Treatment Of Relapsed Acute Promyelocytic Leukemia 38

Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Table


Number of Products under Development for Acute Promyelocytic Leukemia, H2 2013 7
Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Acute Promyelocytic Leukemia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2013 16
Assessment by Monotherapy Products, H2 2013 17
Number of Products by Stage and Target, H2 2013 19
Number of Products by Stage and Mechanism of Action, H2 2013 21
Number of Products by Stage and Route of Administration, H2 2013 22
Number of Products by Stage and Molecule Type, H2 2013 24
Number of Products by Stage and Therapeutic Class, H2 2013 26
Acute Promyelocytic Leukemia Therapeutics - Recent Pipeline Updates, H2 2013 35
Acute Promyelocytic Leukemia - Dormant Projects, H2 2013 36

List of Chart


Number of Products under Development for Acute Promyelocytic Leukemia, H2 2013 7
Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Assessment by Monotherapy Products, H2 2013 17
Number of Products by Top 10 Target, H2 2013 18
Number of Products by Stage and Top 10 Target, H2 2013 19
Number of Products by Top 10 Mechanism of Action, H2 2013 20
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 21
Number of Products by Stage and Top 10 Route of Administration, H2 2013 22
Number of Products by Top 10 Molecule Type, H2 2013 23
Number of Products by Stage and Top 10 Molecule Type, H2 2013 24
Number of Products by Top 10 Therapeutic Class, H2 2013 25
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *